NSCLC cells with KRAS mutations showed detectable DNA damage and increased sensitivity to radiotherapy upon FAK gene knockdown using CRISPR/Cas9 (Tang et al., 2016). The gene discussed is PTK2; the disease is non-small cell lung carcinoma.